Harrow (HROW) Shares Outstanding (2010 - 2026)
Harrow's (HROW) quarterly Shares Outstanding (Entity) came in at $37.3 million in Q1 2026, up 4.53% year-on-year from $35.7 million in Q1 2025, and little changed quarter-over-quarter from $37.2 million in Q4 2025.
Harrow (HROW) Shares Outstanding (2010 - 2026) Analysis & Trends
Harrow's Shares Outstanding (Entity) history runs 15 years deep, the most recent figure standing at $37.3 million for Q1 2026.
- On a quarterly basis, Shares Outstanding (Entity) rose 4.53% year-over-year to $37.3 million in Q1 2026; TTM through Mar 2026 was $37.3 million, a 4.53% increase from a year earlier, with the FY2025 full-year figure at $37.2 million, up 4.51% from the prior year.
- Shares Outstanding (Entity) steadied at $37.3 million in Q1 2026 per HROW's latest filing, from $37.2 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $37.3 million in Q1 2026 and bottomed at $27.0 million in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $35.4 million (2024), against an average of $33.4 million.
- Across the five-year window, Shares Outstanding (Entity) climbed 0.64% in 2022 and climbed 29.71% in 2023, its largest moves.
- Year by year, Shares Outstanding (Entity) stood at $29.9 million in 2022, then grew by 17.61% to $35.2 million in 2023, then advanced by 1.29% to $35.6 million in 2024, then grew by 4.51% to $37.2 million in 2025, then climbed by 0.11% to $37.3 million in 2026.
- Per Business Quant, the three latest HROW Shares Outstanding (Entity) figures stand at $37.3 million (Q1 2026), $37.2 million (Q4 2025), and $37.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | 8.98 Bn |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 1.16 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 422.10 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 1.58 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 43.50 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | 31.59 Bn |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 100.50 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 497.70 Mn |
| 10 | Harrow | 1.43 Bn | 1.34 Bn | 27.05 Mn | 37.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.23 Mn |
| Dec 31, 2025 | 36.76 Mn |
| Sep 30, 2025 | 37.15 Mn |
| Jun 30, 2025 | 36.79 Mn |
| Mar 31, 2025 | 35.83 Mn |
| Dec 31, 2024 | 35.65 Mn |
| Sep 30, 2024 | 35.70 Mn |
| Jun 30, 2024 | 35.62 Mn |
| Mar 31, 2024 | 35.47 Mn |
| Dec 31, 2023 | 32.62 Mn |
| Sep 30, 2023 | 34.26 Mn |
| Jun 30, 2023 | 30.46 Mn |
| Mar 31, 2023 | 30.29 Mn |
| Dec 31, 2022 | 27.46 Mn |
| Sep 30, 2022 | 27.35 Mn |
| Jun 30, 2022 | 27.30 Mn |
| Mar 31, 2022 | 27.23 Mn |
| Dec 31, 2021 | 26.76 Mn |
| Sep 30, 2021 | 27.11 Mn |
| Jun 30, 2021 | 26.74 Mn |